NCT00441584 - The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL

PegIntron (peginterferon alfa-2b)

Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

DRUG

Rebetol (ribavirin)

200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks